Table 1 Demographics and baseline characteristics
From: Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
BDP/FF | FP/S | |
|---|---|---|
(N = 211) | (N = 207) | |
Gender: | ||
Male (%) | 155 (73.5) | 143 (69.1) |
Female (%) | 56 (26.5) | 64 (30.9) |
Age, years | 63.8 (8.2) | 63.7 (8.6) |
BMI, kg/m 2 | 26.16 (5.37) | 27.02 (5.60) |
Smoking habits: | ||
Ex-smokers (%) | 106 (50.2) | 121 (58.5) |
Current smokers (%) | 105 (49.8) | 86 (41.5) |
No. of pack years | 40.1 (20.4) | 41.9 (23.0) |
Previous treatments* (%) | ||
Long-acting anticholinergic | 139 (65.9) | 140 (63.6) |
LABA | 51 (24.2) | 44 (21.3) |
ICS/LABA fixed combination | 119 (56.4) | 126 (60.9) |
ICS | 36 (17.1) | 28 (13.5) |
Pre-dose FEV1, litre | 1.13 (0.40) | 1.10 (0.36) |
Pre-bronchodilator FEV1, litre † | 1.13 (0.33) | 1.10 (0.30) |
Post- bronchodilator FEV1, litre † | 1.31 (0.32) | 1.29 (0.33) |
Post- bronchodilator FEV1/FVC (%)† | 44.2 (9.7) | 44.4 (9.8) |
Post- bronchodilator FEV1 (% predicted normal)† | 46.5 (9.6) | 46.4 (9.8) |
FEV1 post-bronchodilator change (%)† | 17.5 (11.0) | 17.8 (11.0) |
BDI score | 6.1 (1.8) | 6.1 (1.7) |
SGRQ score | 47.0 (16.7) | 45.2 (16.5) |
pre-dose 6MWT, metres | 352 (106) | 364 (109) |
Symptom score | 6.27 (3.57) | 6.05 (3.72) |
Symptom-free days (%) | 7.55 (20.14) | 7.21 (20.59) |
Rescue medication-free days (%) | 44.27 (42.10) | 39.69 (39.86) |
Patients with no exacerbations in the previous year | 116 (55.0%) | 108 (52.2%) |